

National e-library for standardized chemotherapy regimens

AnnSofie Fyhr and Ulrika Landin, Operations Developer

Ann-sofie.fyhr@skane.se and Ulrika.landin@skane.se

Conflicts of interest – none declared

Key messages

- Have an organisation like the Regional cancer centres (RCC) to operate from, with secured funding, technical platform and a quality system
- User knowledge and feedback is the key to success
- Make it easy and work with standardization, continuous improvement and evaluation





AUGUST 2006

Distributed to:

- Chief Executives
- Directors of Clinical Governance
- Directors of Clinical Operations

Action required by:

- Directors of Clinical Governance
- Directors of Clinical Operations

For response by:

- Directors of Clinical Governance

Safety Alert 04/06

Safe Use of Vincristine

Vincristine is an intravenous chemotherapy drug

Vincristine, a medicine commonly used in the treatment of leukaemias and lymphomas, is neurotoxic and **must only be administered intravenously**.

Background

Vincristine **must not** be administered intrathecally.

Sentinel events associated with the inadvertent intrathecal administration of vincristine have been reported in Australia and overseas. **This error results in a fatal outcome in 85% of cases with devastating neurological effects in the few survivors.**

Recently in NSW a near miss involving an intravenous chemotherapy agent was reported. The drug was almost injected intrathecally but implementation of local policy averted this error.

Implementing the actions in this Safety Alert will reduce the risk of inappropriate intrathecal injections.

ISMP List of High-Alert Medications in Acute Care Settings

<https://www.ismp.org>

High-alert medications are drugs that bear a heightened risk of causing significant patient harm when they are used in error. Although mistakes may or may not be more common with these drugs, the consequences of an error are clearly more devastating to patients

Chemotherapy regimen - Breastcancer

Pembrolizumab-Paklitaxel weekly 21 days with pause

C50

Cycle intervall: 21 days

Treatment intention: Palliative

Overview

Drug


Substance	Administration	Dilution	Infusion time	Dose/adm.	Dosing	Max dose/adm.	Max ack. dose
1. Pembrolizumab	Intravenous infusion	100 ml Sodium chlorid 0,9% infusion	30 min.	200 mg	Standard dose		
2. Paklitaxel	Intravenous infusion	250 ml Sodium chlorid 0,9% infusion	60 min.	80 mg/m ²	BSA		


Regimen description

Day	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	New cycle day 22
1. Pembrolizumab	x1																					
2. Paklitaxel	x1							x1														

Emetogenicity: Low

Chemotherapy process – joint tool






Bröstcancer

Nationellt vårdprogram



Technical platform



<https://kunskapsbanken.cancercentrum.se/>

- ✓ Support documents
- ✓ Newsletters

Download för PDF:s and XML-files for CPOE systems

Computerised physician order entry

<https://kunskapsbanken.cancercentrum.se/>


Kunskapsbanken[Vårdprogram](#)[Vårdförlopp](#)[Stöddokument](#)[Läkemedelsregimer](#) ▾[Basfakta om läkemedel](#)


☰
Meny

Välj kunskapsstöd

Nationella vårdprogram


Rekommendationer om utredning, behandling, omvårdnad, rehabilitering och uppföljning av patienter med cancer.




[Vårdprogram](#) 

Standardiserade vårdförlopp


Kriterier för välgrundad misstanke, beskrivning av utredningar och ledtider för första behandling.





[Vårdförlopp](#) 


Nationella regimbiblioteket

Beskrivningar av hur antitumorala läkemedel ska doseras och kombineras. Här finns även information till patienter.



[Läkemedelsregimer](#) 

[Basfakta om läkemedel](#) 

[Barncancer](#) 

Joint effort



Reference group




Task specific team



E-library team


FEEDBACK

- E-mail from users
- Pharmaceutical companies
- Interviews
- Web survey
- Website statistics
- Professional evaluation of the website.



Key messages

- Have an organisation like the Regional cancer centres (RCC) to operate from, with secured funding, technical platform and a quality system
- User knowledge and feedback is the key to success
- Make it easy and work with standardization, continuous improvement and evaluation





CONFEDERATION
OF REGIONAL
CANCER CENTRES

